Evidence map›Paper›PMID 38747221›Full record

ReviewCurrent diabetes reviews2025

Cell Therapies and Gene Therapy for Diabetes: Current Progress.

Leila Ghassemifard, Masumeh Hasanlu, Negin Parsamanesh, Stephen L Atkin, Wael Almahmeed, Amirhossein Sahebkar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Leila GhassemifardDepartment of Physiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Masumeh HasanluDepartment of Internal Medicine, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Negin ParsamaneshMetabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
Stephen L AtkinResearch Department, Royal College of Surgeons in Ireland Bahrain, Adliya, Bahrain.
Wael AlmahmeedHeart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Amirhossein SahebkarCenter for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epidemic of diabetes continues to be an increasing problem, and there is a need for new therapeutic strategies. There are several promising drugs and molecules in synthetic medicinal chemistry that are developing for diabetes. In addition to this approach, extensive studies with gene and cell therapies are being conducted. Gene therapy is an existing approach in treating several diseases, such as cancer, autoimmune diseases, heart disease and diabetes. Several reports have also suggested that stem cells have the differentiation capability to functional pancreatic beta cell development in vitro and in vivo, with the utility to treat diabetes and prevent the progression of diabetes-related complications. In this current review, we have focused on the different types of cell therapies and vector-based gene therapy in treating or preventing diabetes.

Indexed as

Cell- and Tissue-Based TherapyDiabetes MellitusGenetic TherapyAnimalsHumansInsulin-Secreting CellsStem Cell Transplantationcell therapyDiabetesgene therapypancreatic beta cellsstem cellsvector.

Identifiers

PMID38747221

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.